{"id":7683,"date":"2025-10-16T08:25:00","date_gmt":"2025-10-16T06:25:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-utvalt-som-finalist-i-fierce-innovation-awards-life-sciences-edition-2025\/"},"modified":"2025-11-06T08:12:14","modified_gmt":"2025-11-06T07:12:14","slug":"nanexa-utvalt-som-finalist-i-fierce-innovation-awards-life-sciences-edition-2025","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-utvalt-som-finalist-i-fierce-innovation-awards-life-sciences-edition-2025\/","title":{"rendered":"Nanexa utvalt som finalist i Fierce Innovation Awards Life Sciences Edition 2025"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Nanexa har n\u00f6jet att meddela att bolaget har blivit utvalt som finalist i kategorin Drug Delivery Technology av den ledande branschtidningen Fierce Life Sciences. De \u00e5rliga Fierce Life Sciences Innovation Awards lyfter fram och visar upp framst\u00e5ende innovationer som driver utvecklingen inom life science-teknologier. Deras expertpanel av jurymedlemmar har identifierat Nanexa som ett f\u00f6retag vars banbrytande l\u00f6sningar har potential att skapa effektiviseringar, \u00f6ka patientengagemanget eller revolutionera l\u00e4kemedelsindustrin.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>David Westberg, vd f\u00f6r Nanexa, kommenterade: \u201dHela Nanexas team \u00e4r v\u00e4ldigt glada \u00f6ver att potentialen i v\u00e5r teknologi har uppm\u00e4rksammats av Fierce Life Sciences. PharmaShell-plattformen \u00e4r en verkligt banbrytande teknik f\u00f6r l\u00e4kemedelsformulering som anv\u00e4nder atomic layer deposition (ALD)-teknik f\u00f6r att kapsla in partiklar av aktiva l\u00e4kemedelssubstanser (API:er) i ett extremt tunt skal, vilket m\u00f6jligg\u00f6r f\u00f6rl\u00e4ngd och kontrollerad fris\u00e4ttning under m\u00e5nader med o\u00f6vertr\u00e4ffad precision. Det h\u00e4r kommer att hj\u00e4lpa till att behandla en m\u00e4ngd olika kroniska tillst\u00e5nd och g\u00f6ra stor skillnad f\u00f6r miljontals patienter v\u00e4rlden \u00f6ver, d\u00e4r m\u00e5nga av dem har sv\u00e5rt att f\u00f6lja dagliga doseringsrutiner.\u201d<\/p>\n<p>PharmaShell har visat sig l\u00e4mplig f\u00f6r l\u00e5ngtidsverkande och kontrollerad fris\u00e4ttning av olika API:er, inklusive biologiska l\u00e4kemedel, och har nyligen presenterat kliniskt proof-of-concept f\u00f6r en m\u00e5nadsverkande GLP-1-formulering. PharmaShell-formuleringarna kan m\u00f6jligg\u00f6ra behandling av en rad olika sjukdomar, s\u00e5som typ 2-diabetes, obesitas, cancer, hj\u00e4rt-k\u00e4rlsjukdomar och psykiatriska sjukdomar med bara en injektion per m\u00e5nad eller \u00e4nnu mer s\u00e4llan.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr\/>\n<p>David Westberg \u2013 vd, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" rel=\"noopener\" target=\"_blank\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" rel=\"noopener\" target=\"_blank\">www.nanexa.com<\/a><\/p>\n<p>Bolagets Certified Adviser \u00e4r Tapper Partners AB.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr\/>\n<p>Nanexa introducerar kontroll, precision och m\u00e5ngsidighet till l\u00e4kemedelsformuleringar med hj\u00e4lp av ALD-teknik (Atomic Layer Deposition). F\u00f6retagets patenterade PharmaShell\u00ae-plattform \u00e4r ett unikt drug delivery-system som m\u00f6jligg\u00f6r h\u00f6g drug load vilket ger l\u00e5g injektionsvolym och skapar en ny generation formuleringar, s\u00e5 kallade \u201dsuper generics\u201d som ger st\u00f6rre bekv\u00e4mlighet och minskar kostnaderna vid behandling av allehanda sjukdomstillst\u00e5nd som metabola sjukdomar, t.ex. typ 2-diabetes och obesitas, hematologi\/onkologi, hj\u00e4rt-k\u00e4rlsjukdomar, psykiatri och m\u00e5nga andra.<br \/>Nanexa utvecklar egna l\u00e4kemedelsprodukter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/e38ebefd-742f-4cd0-a02a-9ee92f1e49cf\/nanexa-utvalt-som-finalist-i-fierce-innovation-awards-life-sciences-edition-2025.pdf\" rel=\"noopener\" target=\"_blank\">Nanexa utvalt som finalist i Fierce Innovation Awards Life Sciences Edition 2025<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanexa har n\u00f6jet att meddela att bolaget har blivit utvalt som finalist i kategorin Drug Delivery Technology av den ledande branschtidningen Fierce Life Sciences. De \u00e5rliga Fierce Life Sciences Innovation Awards lyfter fram och visar upp framst\u00e5ende innovationer som driver utvecklingen inom life science-teknologier. Deras expertpanel av jurymedlemmar har identifierat Nanexa som ett f\u00f6retag vars banbrytande l\u00f6sningar har potential att skapa effektiviseringar, \u00f6ka patientengagemanget eller revolutionera l\u00e4kemedelsindustrin.<\/p>\n","protected":false},"template":"","class_list":["post-7683","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-ext-nq_sv","mfn-news-tag-mfn-ext-nq-company-announcement_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa utvalt som finalist i Fierce Innovation Awards Life Sciences Edition 2025 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-utvalt-som-finalist-i-fierce-innovation-awards-life-sciences-edition-2025\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa utvalt som finalist i Fierce Innovation Awards Life Sciences Edition 2025 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa har n\u00f6jet att meddela att bolaget har blivit utvalt som finalist i kategorin Drug Delivery Technology av den ledande branschtidningen Fierce Life Sciences. De \u00e5rliga Fierce Life Sciences Innovation Awards lyfter fram och visar upp framst\u00e5ende innovationer som driver utvecklingen inom life science-teknologier. Deras expertpanel av jurymedlemmar har identifierat Nanexa som ett f\u00f6retag vars banbrytande l\u00f6sningar har potential att skapa effektiviseringar, \u00f6ka patientengagemanget eller revolutionera l\u00e4kemedelsindustrin.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-utvalt-som-finalist-i-fierce-innovation-awards-life-sciences-edition-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-06T07:12:14+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-utvalt-som-finalist-i-fierce-innovation-awards-life-sciences-edition-2025\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-utvalt-som-finalist-i-fierce-innovation-awards-life-sciences-edition-2025\\\/\",\"name\":\"Nanexa utvalt som finalist i Fierce Innovation Awards Life Sciences Edition 2025 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2025-10-16T06:25:00+00:00\",\"dateModified\":\"2025-11-06T07:12:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-utvalt-som-finalist-i-fierce-innovation-awards-life-sciences-edition-2025\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-utvalt-som-finalist-i-fierce-innovation-awards-life-sciences-edition-2025\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-utvalt-som-finalist-i-fierce-innovation-awards-life-sciences-edition-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa utvalt som finalist i Fierce Innovation Awards Life Sciences Edition 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa utvalt som finalist i Fierce Innovation Awards Life Sciences Edition 2025 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-utvalt-som-finalist-i-fierce-innovation-awards-life-sciences-edition-2025\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa utvalt som finalist i Fierce Innovation Awards Life Sciences Edition 2025 - Nanexa AB","og_description":"Nanexa har n\u00f6jet att meddela att bolaget har blivit utvalt som finalist i kategorin Drug Delivery Technology av den ledande branschtidningen Fierce Life Sciences. De \u00e5rliga Fierce Life Sciences Innovation Awards lyfter fram och visar upp framst\u00e5ende innovationer som driver utvecklingen inom life science-teknologier. Deras expertpanel av jurymedlemmar har identifierat Nanexa som ett f\u00f6retag vars banbrytande l\u00f6sningar har potential att skapa effektiviseringar, \u00f6ka patientengagemanget eller revolutionera l\u00e4kemedelsindustrin.","og_url":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-utvalt-som-finalist-i-fierce-innovation-awards-life-sciences-edition-2025\/","og_site_name":"Nanexa AB","article_modified_time":"2025-11-06T07:12:14+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-utvalt-som-finalist-i-fierce-innovation-awards-life-sciences-edition-2025\/","url":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-utvalt-som-finalist-i-fierce-innovation-awards-life-sciences-edition-2025\/","name":"Nanexa utvalt som finalist i Fierce Innovation Awards Life Sciences Edition 2025 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2025-10-16T06:25:00+00:00","dateModified":"2025-11-06T07:12:14+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-utvalt-som-finalist-i-fierce-innovation-awards-life-sciences-edition-2025\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-utvalt-som-finalist-i-fierce-innovation-awards-life-sciences-edition-2025\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-utvalt-som-finalist-i-fierce-innovation-awards-life-sciences-edition-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa utvalt som finalist i Fierce Innovation Awards Life Sciences Edition 2025"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}